The BRCA1 gene from individuals at risk of breast and ovarian cancers can be screened for the presence of mutations. However, the cancer association of most alleles carrying missense mutations is unknown, thus creating significant problems for genetic counseling. To increase our ability to identify cancer-associated mutations in BRCA1, we set out to use the principles of protein three-dimensional structure as well as the correlation between the cancer-associated mutations and those that abolish transcriptional activation. Thirty-one of 37 missense mutations of known impact on the transcriptional activation function of BRCA1 are readily rationalized in structural terms. Loss-of-function mutations involve nonconservative changes in the core of the BRCA1 C-terminus (BRCT) fold or are localized in a groove that presumably forms a binding site involved in the transcriptional activation by BRCA1; mutations that do not abolish transcriptional activation are either conservative changes in the core or are on the surface outside of the putative binding site. Next, structurebased rules for predicting functional consequences of a given missense mutation were applied to 57 germ-line BRCA1 variants of unknown cancer association. Such a structure-based approach may be helpful in an integrated effort to identify mutations that predispose individuals to cancer.
INTRODUCTION
Many germ-line mutations in the human BRCA1 gene are associated with inherited breast and ovarian cancers (1, 2) . This information has allowed clinicians and genetic counselors to identify individuals at high risk for developing cancer. However, the disease association of over 350 missense mutations remains unclear, primarily because their relatively low frequency and ethnic specificity limit the usefulness of the population-based statistical approaches to identifying cancer-causing mutations. To address this problem, we use here the threedimensional structure of the human BRCA1 BRCT domains to assess the transcriptional activation functions of BRCA1 mutants. Our study is made possible by the recently determined sequences (3) (4) (5) (6) and three-dimensional structures of the BRCA1 homologs (7, 8) . In addition, we benefited from prior studies that attempted to rationalize and predict functional effects of mutations in various proteins (9 -12) , including those of BRCA1 (13, 14) .
BRCA1 is a nuclear protein that activates transcription and facilitates DNA damage repair (15, 16) . The tandem BRCT domains at the COOH-terminus of BRCA1 are involved in several of its functions, including modulation of the activity of several transcription factors (15) , binding to the RNA polymerase II holoenzyme (17) , and activating transcription of a reporter gene when fused to a heterologous DNA-binding domain (18, 19) . Importantly, cancer-associated mutations in the BRCT domains, but not benign polymorphisms, inactivate transcriptional activation and binding to RNA polymerase II (18 -21) . These observations suggest that abolishing the transcriptional activation function of BRCA1 leads to tumor development and provides a genetic framework for characterization of BRCA1 BRCT variants.
MATERIALS AND METHODS
The multiple sequence alignment (MSA) of orthologous BRCA1 BRCT domains from seven species, including Homo sapiens (GenBank accession number U14680), Pan troglodytes (AF207822), Mus musculus (U68174), Rattus norvegicus (AF036760), Gallus gallus (AF355273), Canis familiaris (U50709), and Xenopus laevis (AF416868), was obtained by using program ClustalW (22) and contains only one gapped position ( Supplementary Fig. 1 ). According to PSI-BLAST (23) , the latter six sequences are the only sequences in the nonredundant protein sequence database at National Center for Biotechnology Information that have between 30% and 90% sequence identity to the human BRCA1 BRCT domains (residues 1649 -1859).
The multiple structure-based alignment of the native structures of the BRCT-like domains was obtained by the SALIGN command in MODELLER ( Supplementary Fig. 2 ). It included the experimentally determined structures of the two human BRCA1 BRCT domains (Protein Data Bank code 1JNX; Refs. 8, 24) , rat BRCA1 BRCT domains (1L0B; Ref. 7) , human p53-binding protein (1KZY; Ref. 7) , human DNA-ligase III␣ (1IMO; Ref. 25) , and human XRCC1 protein (1CDZ; Ref. 13) . Structure variability was defined by the root-mean-square deviation among the superposed C␣ positions, as calculated by the COMPARE command of MODELLER. The purpose of these calculations was to gain insight into the variability of surface-exposed residues (left panel in Fig. 2 ). In conjunction with observed mutation clustering, these data may point to putative functional site(s) on the surface of BRCT repeats.
Comparative protein structure modeling by satisfaction of spatial restraints, implemented in the program MODELLER-6 (26), was used to produce a three-dimensional model for each of the 94 mutants. The crystallographic structure of the human wild-type BRCA1 BRCT domains was used as the template for modeling (8) . The four residues missing in the crystallographic structure (1694 and 1817-1819) were modeled de novo (27) . All of the models are available in the BRCA1 model set deposited in our ModBase database of comparative protein structure models (28). 6 For the native structure of the human BRCT tandem repeat and each of the 94 mutant models, a number of sequence and structure features were calculated. These features were used in the classification tree in Fig. 3 (values for all 94 mutations are given in Supplementary Tables 1 and 2) .
Buriedness. Accessible surface area of an amino acid residue was calculated by the program DSSP (29) and normalized by the maximum accessible surface area for the corresponding amino acid residue type. A residue was considered exposed if its accessible surface area was larger than 40Å 2 and if its relative accessible surface area was larger than 9% and buried otherwise. A mutation of a more exposed residue is less likely to change the structure and therefore its function. (18, 19, 36) . Found in an early-onset breast tumor, the mutant allele (present in the germ line) was absent in control population and was retained in the tumor (41). S1715N S ⅷ Not explained. Likely amino acid substitution. No detectable activity in transcription assays (21) . Found in an early-onset breast cancer case but segregation was not ascertained (42) . S1715R S ⅷ ⅷ Large volume change at rigid position and in rigid neighborhood, charge change. Segregates with disease in at least one family and had no detectable activity in transcription assays (21) . S1722F S ⅷ Very large volume change at flexible position, unlikely amino acid substitution at completely preserved position, disrupts WXXXC/S motif and 1718-1722 interaction (13) . No detectable activity in transcription assays at 37°C (39). D1733G DEH ⅜ Likely amino acid substitution on the surface outside of known functional sites. Activity in transcription assays comparable to wild-type BRCA1 (37). F1734L F ⅷ Unlikely amino acid substitution at completely preserved position. No detectable activity in transcription assays at 37°C (38) . G1738E G ⅷ Buried, charge change, unlikely amino acid substitution at completely preserved position. No detectable activity in transcription assays (37) . G1743R G ⅷ Unlikely amino acid substitution at completely preserved position. No detectable activity in transcription assays (38) . P1749R P ⅷ Charge change, unlikely amino acid substitution at completely preserved position. No detectable activity in transcription assays and partial activity in small colony phenotype test (19, 36) . Found in the germ line in an ovarian cancer family and not present in controls but segregation was not determined (43 (37) . M1775E M ⅷ Charge change, two-class polarity change, unlikely amino acid substitution at completely preserved position, BRCT-repeat interface (8) . No detectable activity in transcription assays (18) . M1775K M ⅷ Charge change, two-class polarity change, unlikely amino acid substitution at completely preserved position, BRCT-repeat interface (8) . No detectable activity in transcription assays (18) . M1775R M ⅷ ⅷ Charge change, two-class polarity change, unlikely amino acid substitution at completely preserved position, BRCT-repeat interface (8) . No detectable activity in transcription assays or small colony phenotype test (18, 19, 37) . Found in an early-onset breast tumor, the mutant allele (present in the germ line) was absent in control population and was retained in the tumor (41) . Segregates with disease (1). M1775V M ⅜ Not explained. Unlikely amino acid substitution at completely preserved position, BRCT-repeat interface (8) . Activity in transcription assays comparable to wild-type BRCA1 (18) . L1780P L ⅷ Unlikely amino acid substitution at completely preserved position, helix breaker. No detectable activity in transcription assays (37) . P1806A PLAS ⅜ Likely amino acid substitution, ЈAЈ allowed in multiple sequence alignment. Activity in transcription assays comparable to wild-type BRCA1 (37). I1807S IVL ⅷ Large volume change at rigid position and in rigid neighborhood. No detectable activity in transcription assays (38) . V1833E V ⅷ Charge change, two-class polarity change, and unlikely amino acid substitution at completely preserved position. No detectable activity in transcription assays (37) . A1843T AS ⅷ Not explained. BRCT-repeat interface (8) . No detectable activity in transcription assays (38) . Found in an ovarian cancer case but segregation was not determined (44) .
a Amino acid residues present at the same position in the BRCA1 orthologs (ЈMaterials and Methods;Ј Supplementary Fig. 1 ). ⅜ indicates a presumed benign mutation, and ⅷ indicates a presumed cancer-associated mutation.
b Transcription activity when fused to a heterologous DNA binding domain; ⅷ denotes loss of function and ⅜ denotes activity comparable to that of wild-type BRCA1. c C. Phelan, S. Narod and A. Monteiro, unpublished results.
Functional Site. The putative functional site was visually assigned to the surface groove that contains the deleterious mutants (Fig. 2) ; it consists of residue positions with accessible surface area Ͼ9%, as follows: 1654 -1657, 1659, 1662, 1663, 1666, 1676, 1678, 1698 -1702, 1773, 1774, 1811-1813, 1834, and 1836. A mutation in the functional site is more likely to abolish the function.
Residue Rigidity. A residue isotropic temperature factor (B-factor) was the mean of its atomic B-factors as determined by X-ray crystallography of the native structure; it was also normalized by the mean and standard deviation (SD) of all residue B-factors in the protein chain. A mutation of a less rigid residue at a buried position is less likely to change the structure and therefore its function.
Neighborhood Rigidity. Neighborhood of a residue was defined by the residues that have at least one atom within 5Å of any atom of the central residue. Neighborhood B-factor of a residue was defined to be the mean value of the B-factors of the residues in the neighborhood; it was also normalized by the mean and SD of all neighborhood B-factors for the neighborhoods of the same size. A mutation of a buried residue in a less rigid neighborhood is less likely to change the structure and therefore its function.
Volume Change. Volume change was defined solely by the type of residue substitution (30) . A large change in the volume of the amino acid residue type was considered destabilizing to the structure and therefore its function, especially when buried at a rigid position.
Charge Change. Charge change was defined solely by the type of residue substitution (30) . Mutations corresponding to changes in charge at buried positions are more likely to change the structure and therefore its function.
Polarity Change. Polarity change was defined solely by the type of residue substitution. Amino acid residue types were classified into three classes according to their hydrophobicity: 0 ' {LIFWCMVY}, 1 ' {PATGS}, 2 ' {HQRKNED} (30) . Mutations corresponding to changes in polarity at buried positions are more likely to change the structure and therefore its function.
Mutation Likelihood. Mutation likelihood of a residue substitution at a given MSA position reflects the "background" substitution probabilities in the BLOSUM62 matrix as well as the actually observed substitutions at the given position in the MSA of the BRCA1 BRCT orthologs (Supplementary Fig. 1 ; Refs. 4 -6, 9, 31). The scores are centered on zero, with negative values corresponding to less likely substitutions. Unlikely mutations are more likely to change the structure and function.
Phylogenetic Entropy. Sequence variability was defined for every column in the MSA of the BRCA1 BRCT orthologs (Supplementary Fig. 1 ) by ⌺ p ln p, where p is the observed relative frequency of residue type i (Fig. 2, right  panel) . Mutations at evolutionarily conserved positions are more likely to change the structure and function.
Helix/Turn Breaker. Secondary structure assignment was calculated by DSSP (29) . A "helix breaker" mutation was defined as any mutation into the glycine or proline residues at a helical position; a "turn breaker" mutation was defined as any replacement of the glycine or proline residues at a turn position.
Visualization and analysis of the mutations were facilitated by the program DINO. 7 Transcriptional assays for testing our predictions were performed as described previously (21) . The wild-type BRCA1 sequence (residues 1396 -1863) fused in frame to the LexA DNA-binding domain was used as the wild-type control and for introducing mutations M1775R, Y1853X, M1689R, and W1718C by site-directed mutagenesis. EGY48 yeast cells were cotransformed with the constructs and pRB1840, which contains a lacZ reporter gene under the control of a LexA operator, and tested in liquid ␤-galactosidase assays. For mammalian transcription assays, BRCA1 constructs were subcloned in frame to GAL4 DNA-binding domain in pCDNA3. GAL4 DNAbinding domain fusion constructs were cotransfected into human 293T cells with pG5Luc, which contains a firefly luciferase gene under the control of five GAL4 binding sites as a reporter for the assay. Transfections were normalized with an internal control phRG-TK (Promega), which contains a Renilla luciferase gene under a constitutive thymidine kinase-basal promoter.
RESULTS AND DISCUSSION
We tabulated a total of 94 missense mutations in the human BRCA1 BRCT domains (Tables 1 and 2; Fig. 1 ). These mutations occurred naturally or were obtained via random mutagenesis. Tran-7 http://www.dino3d.org. Fig. 1 . Classification of the 94 missense mutations in the human BRCA1 BRCT domains analyzed in this study. The mutants were divided into groups depending on information about their cancer association and transcriptional activation function (Tables 1 and 2 ). The mutations at solventexposed positions are underlined ("Materials and Methods"). PT ⅜ Likely amino acid substitution. a Comments list the rationalizations for each of the 57 predictions, as produced by the classification tree (Fig. 3) . ⅜ indicates a predicted benign mutation, and ⅷ indicates a predicted cancer-associated mutation.
scriptional activation function of 37 of 94 mutants has been tested (Fig. 1, rows 1 and 2) . Eight of the 37 mutants could be tentatively classified either as cancer-associated or benign following established genetic criteria (Ref. 32 ; Fig. 1, columns 1 and 2) . The basis of each classification is outlined in Table 1 .
For the eight mutations with intact transcriptional activation function, there is no evidence of cancer-association; the frequency in control population is equal or higher than in cancer cases, and there is absence of co-segregation in at least one family (Fig. 1, row 2 ; Table  1 ). Conversely, none of the 29 tested mutations without transcriptional activation function are thought to be benign, following the same criteria (Fig. 1, row 2 We first rationalized the functional consequences of the 37 tested mutations in terms of their impact on folding and stability of the native structure and in terms of the integrity of binding sites of the BRCT domains. Next, we used this experience to develop generic rules for prediction of the functional impact of a missense mutation and applied these rules to the remaining 57 functionally uncharacterized mutations listed in Fig. 1 and Table 2 . We then tested two of these predictions by functional assays and segregation analysis.
Missense mutations of BRCA1 are likely to affect transcriptional activation in either one of the following two ways: (a) when they are exposed to the solvent, they may substantially change the structure or chemical nature of functional sites that bind other molecules, or (b) when they are buried in the core, they may prevent folding of the BRCT domains into their native fold or, less likely, affect only the structure of functional sites.
The 37 mutations, including the 8 (Fig. 1, row 2 ) and the 29 mutations (Fig. 1, row 1) with and without transcriptional activation function, respectively, were mapped onto the crystallographic structure of the human BRCA1 BRCT domains (Ref. 8; Fig. 2 ). In addition to this structural mapping, we produced a three-dimensional protein structure model for each mutant and calculated a number of its sequence and structure features ("Materials and Methods"). We used the feature values and their changes between the wild type and the mutant to rationalize the observed effect on transcriptional activation (Table 1; Supplementary Table 1) .
The markedly reduced transcriptional activation activity of the 29 mutations (Fig. 1, row 1) is readily explained by their likely disruption of the structure of the BRCT domain and/or its binding sites that are involved in transcriptional activation. Twenty-three of these 29 mutations occur at buried positions and involve amino acid residue types with dissimilar charge, hydrophobicity, size, or secondary structure propensity (Fig. 1, row 1, not underlined) . Thus, they are expected to disrupt the structure and therefore its function. The remaining six mutations resulting in reduced transcriptional activation are exposed (Fig. 1, row 1, underlined) . Among these six mutations, R1699W and R1699Q replace a conserved residue involved in a salt bridge between the BRCT repeats (8) . Another one of the six mutations (G1743R) occurs at a position that is absolutely conserved among all available orthologs ( Supplementary Fig. 1 ). For the remaining three exposed mutations that abolish transcription, we propose that they disrupt interactions with BRCA1 ligand(s). They are located in a groove formed by both BRCT repeats (L1657P and K1702E) and in the ridge that delimits the groove (E1660G). We suggest that this clustering of residues in a single patch on the surface of BRCA1 highlights a binding site with integrity that is necessary for transcription. Moreover, this putative binding site is relatively conserved in sequence and structure among the BRCA1 homologs ( Fig. 2 ; "Materials and Methods"). These results are in agreement with in vitro binding studies that determined the binding site of BRCA1 to the RNA polymerase holoenzyme via RNA helicase A (17) . Nonconservative substitutions of any amino acid residues that comprise the putative binding site are also likely to affect transcriptional activation. The existence of such a Fig. 2 . Missense mutations on the surface of the human BRCA1 BRCT domains. The solvent-exposed residues with mutations that are known to affect and not affect the transcriptional activation activity of BRCA1 are contoured in red and yellow, respectively (Fig. 1) . The only remaining exposed mutation of known functional impact (P1806A) is on the hidden face of the structure. Conservation of structure ("Materials and Methods;" Supplementary Fig. 2 ) and sequence (see phylogenetic entropy in "Materials and Methods" and Supplementary  Fig. 1 ) are indicated by the intensity of blue on the left and right panels, respectively. The region in violet on the left panel corresponds to the linker between the two domains. The NH 2 -and COOHtermini of the tandem domains are marked on the right panel.
functional region indicates that the tandem BRCT repeats comprise one structural and functional unit, in accordance with previous conclusions (7) .
The lack of impact of the eight mutations that do not disrupt transcriptional activation function (Fig. 1, row 2) can also be rationalized in structural terms. Three of them are exposed on the face away from the putative binding site proposed above, whereas the remaining five mutations are conservative changes in the core of the fold (Table 1 ; Fig. 2 ). Five mutations (G1706A, S1715N, F1761I, M1775V, and A1843T) in the total set of 37, with impact on the transcriptional activation function that is known, could not be readily explained. Possible reasons for the inability to explain these mutants are discussed in detail in Supplementary Table 3 .
Because it was straightforward to use the three-dimensional structure of the BRCA1 domains to rationalize the known functional impact of 32 of the 37 mutations, we derived a set of rules for predicting whether a given mutation inactivates transcriptional activation and therefore correlates with predisposition to cancer. These rules rely on the sequence and structural features that proved informative in explaining the presence or absence of a functional impact of the tested mutations. For example, structural neighborhood around a mutated residue can be rigid, and a mutation can introduce a large change (over 30A
3 ) in the side chain volume. Such a mutation is likely to destabilize or distort local conformation, thus having an effect on the function of the protein. In contrast, a flexible structural neighborhood is expected to accommodate such a substitution without major perturbations in the structure. Moreover, our rules allow for the possibility that very large changes in the side chain volume (over 90A
3 ) can have a significant effect even in a flexible neighborhood. The rules were encoded hierarchically in a "classification tree" scheme ( Fig. 3) and are implemented on the web. 8 Using the classification tree, we predicted the functional consequences of the 57 missense mutations in the BRCT domains that presently lack definitive information about cancer association (Breast Cancer Information Core Database; 9 Table 2; Supplementary Table  2) . Our prediction algorithm assigned functional impact to 32 mutants, whereas 25 were predicted to be benign.
To validate our predictions, we tested prospectively two mutants (Fig. 4, A and B) for which segregation data were available. The W1718C mutation was found in a family with three generations affected where women were diagnosed with either early-onset (Ͻ40-years-old) breast cancer or ovarian cancer. It was present in four of four women with cancer and was absent in three of three at-risk women without cancer. 10 The M1689R mutation also segregated with disease in a large family with several generations affected (Fig. 4C) . Both M1689R and W1718C displayed the loss of function phenotype and segregated with disease in agreement with our predictions (Fig.  4) . Fig. 3 . Classification tree for annotating a given missense mutation in the human BRCA1 BRCT domains. The classification begins at the top (Start) and ends at one of the "ϩ" or "-" leaves. The "ϩ" and "-" indicate mutants with intact (benign) and abolished transcriptional activation function (cancer-associated), respectively. This classification tree correctly rationalizes 32 of the 37 functionally characterized variants ( Table 1 ). The tree was also applied to 57 mutants that have not yet been characterized by experiment (Table 2) . See "Materials and Methods" and Supplementary Material for a detailed description of the features.
To illustrate prediction by the classification tree, we used the mutation M1689R that occurs at a buried position in a relatively rigid neighborhood ( Table 2, Supplementary Table 2 ). Mutations at buried and rigid locations are tolerable only if changes in the residue volume, charge, and polarity are sufficiently small; a volume change of more than one methyl group (30Å 3 ) cannot be accepted. However, the arginine volume is only 18Å 3 larger than that of methionine; therefore, the condition on the maximal allowed volume change is satisfied. At the next checkpoint, the side-chain charge is considered. Because M1689R introduces a positive charge at a buried position, the mutation is considered destabilizing, resulting into the prediction of a loss of function.
The tumor suppressor function of BRCA1 is likely to depend, at least partially, on its transcriptional activity, as suggested previously (18 -21) and supported by the mutation set in Table 1 . Therefore, the ability to predict which mutations do and do not abolish the transcriptional activation function of BRCA1 can be useful in predicting their cancer association. Our analysis, based primarily on the considerations of protein three-dimensional structure, leads to a prediction of cancer association of the mutations that cannot be easily characterized by other approaches, such as population-based statistical genetics. Although all but two of the present predictions are unverified and thus cannot be used as a sole tool for risk assessment and genetic counseling, this structure-based approach may be helpful in an integrated effort, to identify mutations that predispose an individual to breast and ovarian cancers.
